New COPD drug candidate tested for safety in healthy volunteers
NCT ID NCT06908642
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial tested the safety of Hemay005 tablets, a potential new drug for chronic obstructive pulmonary disease (COPD), in 468 healthy Chinese adults. Researchers compared different dosing methods (titration vs. non-titration) to see how they affect side effects. The study focused on adverse events, not on treating COPD.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hemay005 (a PDE4 inhibitor drug)
- What this could lead to
- If successful, this could help determine a safer way to give Hemay005, potentially leading to a new treatment for COPD.
- What could go wrong
- This is an early Phase 1 safety study in healthy people, not patients. It does not test if the drug works for COPD, and side effects are still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital of Wannan Medical College
Wuhu, Anhui, 241000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD